Methods for treating or preventing fatigue using O-carbamoyl-phenylalaninol compounds

Patent metadata

Field	Value
Publication number	US-10507192-B2
Application number	US-201815983944-A
Country	US
Kind code	B2
Filing date	May 18, 2018
Priority date	Jun 22, 2009
Publication date	Dec 17, 2019
Grant date	Dec 17, 2019

Abstract

The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.

First claim

What is claimed is:

1. A method for treating or preventing fatigue which is associated with a disease, disorder or condition selected from the group consisting of depression, cancer, multiple sclerosis, Parkinson's disease, Alzheimer's disease, chronic fatigue syndrome, fibromyalgia, chronic pain, traumatic brain injury, AIDS, and osteoarthritis in a subject, comprising administering to a subject in need thereof, a treatment or prevention effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein
R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms;
x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3;
R 1 and R 2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, heteroaryl, arylalkyl, and cycloalkyl of 3 to 7 carbon atoms;
or R 1 and R 2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.

2. The method of claim 1 , wherein the compound of Formula I is the hydrochloride salt.

3. The method of claim 1 , wherein R is hydrogen and x=1.

4. The method of claim 1 , wherein R, R 1 , and R 2 are all hydrogen and x=1.

5. The method of claim 1 , wherein the compound of Formula I is:

or a pharmaceutically acceptable salt, ester, or prodrug thereof.

6. The method of claim 5 , wherein the compound is

or a pharmaceutically acceptable salt, ester, or prodrug thereof.

7. The method of claim 1 , wherein the compound is administered concurrently with an additional agent or treatment.

8. The method of claim 1 , wherein the treatment or prevention effective amount of the compound is from about 0.01 mg/kg/dose to about 300 mg/kg/dose.

Assignees

• Sk Biopharmaceuticals Co Ltd

Inventors

• Khayrallah Moise A
• Bream Gary
• Butts Stephen E
• Melnick Susan Marie
• Taylor Duncan

Classifications

• A61K31/325 Primary

  Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K31/145) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/137 Primary

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K31/175

  having the group [IMAGE cpc-sch-A61K-0950.gif] , >N—C(O)—N=N— or[IMAGE cpc-sch-A61K-0951.gif] , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof · CPC title